COVID-19, the infectious disease caused by severe acute respiratory syndrome coronavirus-
2 (SARS-CoV-2), is frequently associated with pulmonary thrombotic events, especially in …

The clinical course of coronavirus disease 2019 (COVID-19) is often complicated by the
onset of venous thrombosis and thromboembolism (VTE), encompassing also pulmonary …

I have read with great interest the recent article by Klok et al., showing that the cumulative
incidence of thrombotic complications in patients with COVID-19 admitted to the intensive …

COVID-19 is associated with endothelial activation in the setting of a potent inflammatory
reaction and a hypercoagulable state. The end result of this thromboinflammatory state is an …

Despite the end of the pandemic, coronavirus disease 2019 (COVID-19) remains a major
public health concern. The first waves of the virus led to a better understanding of its …

The rate of thrombotic complications in COVID-19 patients is high and could be associated
with the risk of unfavourable outcomes. Moreover, pulmonary thrombotic events can occur …

COVID-19, the disease responsible for the devastating pandemic that began at the end of
2019, has been associated with a significantly increased risk of pulmonary thrombosis, even …

We read with great interest the recent article by Demelo-Rodríguez et al., reporting that the
incidence of (asymptomatic) deep vein thrombosis (DVT) in patients admitted with COVID-19 …

In coronavirus disease 2019 (COVID-19), thrombus formation is related to the pathogenesis
of acute respiratory distress syndrome (ARDS) and the progression of clinical symptoms …

Introduction Emerging evidence points to an association between severe clinical
presentation of COVID-19 and increased risk of thromboembolism. One-third of patients …